139173-32-3

Usage

Structure

Benzene ring with three hydroxyl (-OH) groups at positions 1, 3, and 5, and an amino (-NH2) group at position 2.

Dyes

Used in the production of various dyes.

Pharmaceuticals

Employed in the synthesis of certain pharmaceuticals.

Hair Dyes

Utilized in the formulation of hair dyes.

Antioxidant Properties

Exhibits antioxidant characteristics, which can help prevent oxidative damage in various systems.

Intermediate in Synthesis

Serves as an intermediate in the synthesis of various organic compounds.

Potential Carcinogenicity

Has been studied for its role in the development of certain types of cancer.

Implications

The compound's effects on health are an area of ongoing research.

Safety Precautions

Due to its potential health effects, appropriate safety measures should be taken when handling or using 1,3,5-Benzenetriol, 2-amino-, such as wearing protective gear and ensuring proper ventilation.

Upstream product

• 7647-01-0 hydrogenchloride 
• 16600-92-3 1,3,5-Trihydroxy-2-nitrobenzene 

Downstream Products

• 1221230-65-4 N-acetylaminophloroglucinol 

Relevant academic research and scientific papers

Recovery of Δf508-CFTR function by analogs of hyaluronan disaccharide

We recently discovered that hyaluronan was exported from fibroblasts by MRP5 and from epithelial cells by cystic fibrosis (CF) transmembrane conductance regulator (CFTR) that was known as a chloride channel. On this basis we developed membrane permeable a

COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING

The present invention relates to a compound which is characterized by the formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof, wherein the ring systems A and B are independently selected from a monosaccharide, aryl (preferably phen

NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN

The present invention relates in general to a compound which is characterized by a formula selected from the following formulas A, B, C, D, E or F; or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the inhibitor(s) of the invention and to their use in the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention furthermore relates to the use of at least one inhibitor of the invention for the preparation of a pharmaceutical composition for the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the inhibitor defined herein in a pharmaceutically acceptable form.